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Challenges recruiting to a proof-of-concept
pharmaceutical trial for a rare disease: the
trigeminal neuralgia experience
Joanna M. Zakrzewska1,9,10* , Joanne Palmer2, Lars Bendtsen3, Giulia Di Stefano4, Dominik A. Ettlin5,
Stine Maarbjerg3, Mark Obermann6,7, Valerie Morisset2, Deb Steiner8, Simon Tate2 and Giorgio Cruccu4
Abstract
Background: This study aimed to describe recruitment challenges encountered during a phase IIa study of
vixotrigine, a state and use-dependent Nav1.7 channel blocker, in individuals with trigeminal neuralgia.
Methods: This was an international, multicenter, placebo-controlled, randomized withdrawal study that included a
7-day run-in period, a 21-day open-label phase, and a 28-day double-blind phase in which patients (planned n = 30)
were randomized to vixotrigine or placebo. Before recruitment, all antiepileptic drugs had to be stopped, except
for gabapentin or pregabalin. After the trial, patients returned to their original medications. Patient recruitment
was expanded beyond the original five planned (core) centers in order to meet target enrollment (total recruiting
sites N = 25). Core sites contributed data related to patient identification for study participation (prescreening
data). Data related to screening failures and study withdrawal were also analyzed using descriptive statistics.
Results: Approximately half (322/636; 50.6%) of the patients who were prescreened at core sites were considered
eligible for the study and 56/322 (17.4%) were screened. Of those considered eligible, 26/322 (8.1%) enrolled in
the study and 6/322 (1.9%) completed the study. In total, 125 patients were screened across all study sites and
67/125 (53.6%) were enrolled. At prescreening, reasons for noneligibility varied by site and were most commonly
diagnosis change (78/314; 24.8%), age > 80 years (75/314; 23.9%), language/distance/mobility (61/314; 19.4%), and
noncardiac medical problems (53/314; 16.9%). At screening, frequently cited reasons for noneligibility included
failure based on electrocardiogram, insufficient pain, and diagnosis change.
Conclusions: Factors contributing to recruitment challenges encountered in this study included diagnosis changes,
anxiety over treatment changes, and issues relating to distance, language, and mobility. Wherever possible, future
studies should be designed to address these challenges.
Trial registration: ClinicalTrials.gov, NCT01540630.
EudraCT, 2010-023963-16. 07 Aug 2015.
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Background
Randomized controlled trials underpin the development
of new drugs and therapies, but challenges with patient re-
cruitment are often encountered, delaying study comple-
tion. A review of 114 multicenter trials conducted by two
UK funding bodies found that fewer than one-third of tri-
als recruited to their original target within the specified
timeframe [1]. Recruitment challenges can be even
tougher when the target population includes patients with
a rare disease [2]. In addition, studies have found that eld-
erly patients and those from racial and ethnic minorities
were underrepresented in pivotal US trials from 2011 to
2013 [3]. It is recognized, however, that the inclusion of
elderly patients, often unqualified to participate in clinical
trials because of comorbid conditions [4], might help to
uncover drug–drug or drug–disease interactions. Failure
to achieve the required sample size affects the reliability
and generalizability of the results.
While there are varied barriers to trial recruitment,
studies have shown that the potential to receive placebo
therapy is of particular concern to patients [5–8]. Other
barriers identified in the literature include trial demands
(procedures/appointments that may cause discomfort or
inconvenience), travel time and travel costs, uncertainty
around effects of treatment or unwillingness to change
medication, and random allocation to study arms [7, 8].
Clinical trials involving therapies for rare diseases re-
quire involvement of multiple sites, usually with rela-
tively few participants from each site, in order to enroll
the target number of participants [2]. Thus, clinical trials
that include patients with a rare disease present an even
greater challenge to physicians, most notably because of
the small numbers of eligible patients and limited treat-
ment options that influence patient reluctance to receive
placebo [5, 9].
Trigeminal neuralgia (TN) is characterized by recur-
rent paroxysms of pain that last from seconds to 2 min
and are triggered by seemingly harmless sensory stimuli
[10]. The pain is best described as like an electric shock,
is of severe intensity, and has a unilateral distribution
that does not extend beyond the trigeminal nerve distri-
bution. TN is considered rare, with incidence in the
range of 4.2–28.9 per 100,000 persons [11–13]. In
addition to the challenges inherent in a rare condition,
there are other unique features of TN that may be asso-
ciated with further challenges to recruitment. For ex-
ample, TN is characterized by very severe pain as well as
unpredictable remission and relapse periods, which may
increase uncertainty around trialing new therapies, result
in variability, and lead to concerns about receiving pla-
cebo treatment. Incidence of TN also increases with age,
with the peak age of onset around age 50–60 years [14],
so the population is skewed toward a harder-to-recruit
older population.
Vixotrigine is a state- and use-dependent inhibitor of
Nav1.7 voltage-gated sodium channels. We recently re-
ported a phase IIa trial (ClinicalTrials.gov NCT01540630
and EudraCT 2010-023963-16) in individuals with TN
that used a randomized withdrawal design to evaluate
the efficacy and safety of vixotrigine treatment [15]. The
randomized withdrawal design was selected to address
concerns around placebo therapy by minimizing the
time patients would spend on placebo in the absence of
effect. Nonetheless, while the trial recruited the required
number of patients, additional centers were required
and the study ran over a longer timeframe than origin-
ally anticipated. We conducted an analysis of the reasons
for recruitment difficulties experienced in the phase IIa
study in order to improve understanding of the chal-
lenges in TN trial recruitment and gather learnings for
future trial design.
Methods
The results from the vixotrigine phase IIa study and the
trial design have been published previously [15, 16]. In
brief, the phase IIa study was an international, double-
blind, multicenter, placebo-controlled, randomized with-
drawal study involving 25 secondary/tertiary care centers
in 12 countries (United Kingdom, Germany, Denmark,
Italy, Switzerland, South Africa, France, Spain, Estonia,
Latvia, Lithuania, and Romania), conducted from April
2012 to February 2014. The study comprised a 7-day
run-in period, a 21-day open-label phase during which
all patients received open-label vixotrigine, and a 28-day
double-blind phase in which patients were randomized
to vixotrigine or placebo. Patients meeting defined re-
sponse criteria during the open-label phase were eligible
for inclusion in the double-blind phase [15, 16]. At the
end of the study, patients went back to their original
medications.
Phase IIa study patient population and target recruitment
Prescreening criteria were determined by the site and
were dependent upon the information available to the
site regarding individual patients. Sites identified patients
via study center databases, advertising through patient
support groups, or recruiting directly from specialized
headache and facial pain clinics. Identified patients
underwent protocol-defined screening (history and phys-
ical, 12-lead electrocardiogram (ECG), clinical labora-
tory) before study enrollment. The diagnosis of TN was
confirmed by a data monitoring committee, comprised
of three lead investigators, before patients were formally
enrolled. Included patients were aged 18–80 years (in-
creased from 70 years in a protocol amendment, May–
August 2012) with active TN. Diagnosis was based on
the second edition of the International Classification of
Headache Disorders [17, 18]. Symptomatic (secondary)
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TN was excluded by imaging. Patients were required to
have at least moderate pain and frequent daily parox-
ysms of pain, defined as at least three paroxysms per
day, each rated at intensity ≥ 4 on a pain intensity nu-
merical rating scale, on ≥ 4 days during the 7 days before
study entry. Known nonresponders to sodium channel
blockers at therapeutic doses were excluded.
This was a phase IIa study and, like most drugs at this
stage, had limited available safety data. As in many
early-phase studies, this knowledge void resulted in ex-
tensive exclusion criteria. Several other factors related to
the limited exposure of the drug to patients resulted in
further exclusion criteria: uncontrolled or poorly con-
trolled hypertension; significant cardiovascular, gastro-
intestinal, or renal disease; or other conditions known to
interfere with the absorption, distribution, metabolism,
or excretion of drugs. Fridericia’s formula had to be <
450 ms in two of three ECGs done at screening. The use
of a wide range of concomitant drugs had to be excluded
and the only anticonvulsants that were allowed were
gabapentin or pregabalin. Patients were not permitted to
use other sodium channel blockers (including carba-
mazepine and oxcarbazepine) during the study. Further
details on inclusion/exclusion criteria are available in
prior publications [15, 16].
The sample size calculation estimated that up to 70
participants were needed for the open-label phase in
order for 30 patients to enter the randomized double-
blind phase and provide sufficient statistical power for
the primary study endpoint (reduction in treatment fail-
ure with vixotrigine vs placebo throughout the double-
blind phase) [16].
Analysis of challenges in recruitment and retention
The current analysis explored the challenges faced in
recruiting participants to the phase IIa study, using pre-
screening and screening data from the five original
(core) sites that maintained a complete record of the
reasons why patients were not recruited into the trial.
Prescreening/screening data were not formally databased
by the study sponsor, but were captured in site records.
The five core sites were Essen (Germany), Glostrup
(Denmark), London (United Kingdom), Rome (Italy),
and Zurich (Switzerland). Because TN frequently pre-
sents in the lower part of the face, patients are often ini-
tially seen by dentists who are skilled at diagnosis of TN.
In Zurich, patients are referred specifically to an oral
medicine unit within a university dental school rather
than a neurology department. The other sites were spe-
cific headache or facial pain units or neuropathic pain
centers, run principally by neurologists. Prescreening at
these sites was based on analysis of database records and
clinic visits.
We also analyzed data on patient withdrawals during
the open-label period of the phase IIa study, based on
the full study population (25 centers) [16], in order to
further understand the factors influencing trial retention.
Results
Prescreening, screening, and enrollment at five core sites
As previously reported, 125 patients were screened;
53.6% (67/125) patients entered the open-label phase,
and 23.2% (29/125) patients were treated in the double-
blind phase [16]. Analyzing data from the five core sites
only, a total of 636 patients were included in prescreen-
ing, of whom 322 (50.6%) were considered eligible for
screening per study criteria and 314 (49.4%) were noneli-
gible. Patients with low or no pain at the time of pre-
screening may have been considered eligible because
their status could change over time. Of the eligible pa-
tients, 56/322 (17.4%) were ultimately screened and 26/
322 (8.1%) were enrolled (of these, 15/322 (4.7%) pro-
ceeded to the randomized double-blind phase). The
core group enrolled 15/29 (51.7%) of the double-blind
population.
Table 1 presents the breakdown of eligible, noneligible,
screened, and enrolled patients by study site. By site, the
proportion of noneligible patients ranged from 11.1%
(Zurich) to 72.4% (Glostrup). The proportion proceed-
ing to screening ranged from 1.3% (London) to 62.5%
(Zurich), and those proceeding to enrollment from 0%
(London) to 18.8% (Zurich).
The mean age of eligible patients tended to be lower
than for noneligible patients. The proportion of male pa-
tients was slightly higher in the eligible group versus the
noneligible group.
Reasons for noneligibility at prescreening and screening
Figure 1 illustrates the reasons documented for nonelig-
ibility at prescreening at the five core sites. The most
common reason for noneligibility at prescreening was
diagnosis change (78/314; 24.8%), followed by age > 80
years (75/314; 23.9%), language/distance/mobility (61/
314; 19.4%), and noncardiac medical problems (53/314;
16.9%), although the relative frequency varied by site
(Fig. 1). Diagnosis change was the most common reason
in Glostrup and Rome, while noncardiac medical prob-
lems was the most common reason in London. At the
Essen site, noncardiac medical problems, age > 80 years,
and language/distance/mobility were the most frequent
reasons. At the Zurich site, only two patients were con-
sidered noneligible (due to noncardiac medical problems
and nonresponder/allergy).
Figure 2 provides a more detailed breakdown of the
prescreening and screening results for the London co-
hort, including reasons for noneligibility and screening
failure. Of the eligible patients following prescreening,
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around two-thirds (53/79; 67.1%) had no or low-level
pain at the time and were judged to not meet entry cri-
teria for moderate pain and frequent daily paroxysms of
pain. Around one-fifth (17/79; 21.5%) declined participa-
tion because they did not want to change from their
current treatment regimen due to fear of losing pain
control. Other reasons for not screening included the
patient’s preference to receive surgery for severe pain,
and reluctance to participate because of previous poor
experience with pregabalin and gabapentin, the only per-
mitted concomitant anticonvulsant medications.
At the Rome site, the majority of prescreened, eligible
patients did not proceed to screening because of reluc-
tance to change treatment regimen (50/84; 59.5%); other
reasons were too little pain (4/84; 4.8%) and preference
to receive surgery for severe pain (2/84; 2.4%). A detailed
breakdown of the reasons for not screening among pre-
screened, eligible patients was not captured for the other
Table 1 Eligible/noneligible patients at prescreening and numbers screened and enrolled for the five core sites
Study
site
Total
pool
Noneligible Eligible Screened Enrolled
n
(% of total
pool)
Mean
age
(years)
Male, n
(% of
noneligible)
Female, n
(% of
noneligible)
n
(% of total
pool)
Mean
age
(years)
Male, n
(% of
eligible)
Female, n
(% of
eligible)
n
(% of
eligible)
n
(% of
eligible)
Essen 109 24 (22.0) 71 7 (29.2) 17 (70.8) 85 (78.0) 5 (5.9) 2 (2.4)
Glostrup 221 160 (72.4) 67 54 (33.8) 106 (66.2) 61 (27.6) 64 29 (47.5) 32 (52.5) 12 (19.7) 6 (9.8)
London 161 82 (50.9) 67 29 (35.4) 53 (64.6) 79 (49.1) 60 30 (38.0) 49 (62.0) 1 (1.3) 0
Rome 130 46 (35.4) 69 14 (30.4) 32 (69.6) 84 (64.6) 63 28 (33.3) 56 (66.7) 28 (33.3) 15 (17.9)
Zurich 15 2 (11.1) 62 0 2 (100.0) 13 (88.9) 58 4 (30.8) 9 (69.2) 10 (62.5) 3 (18.8)
TOTAL 636 314 (49.1) 322 (50.6) 56 (17.4) 26 (8.1)
Fig. 1 Reasons for prescreening failures for the five core sites. Diagnosis change = initial diagnosis of classical trigeminal neuralgia (TN), but later
recorded as not classical trigeminal neuralgia (TN). Age > 80 years = noneligible because of age over the upper limit of 80 years per trial inclusion
criteria. Language/distance/mobility = unable to participate in trial due to language barriers, distance from trial sites, or limited mobility prohibiting
attendance at required study visits. Noncardiac medical problems = noneligible because of noncardiac medical issues prohibited under trial entry
criteria. Cardiac problems = noneligible because of cardiac medical issues prohibited under trial entry criteria, including Fridericia’s formula
requirements (< 450ms in two of three electrocardiograms done at screening). Nonresponder/allergy = noneligible because known nonresponders to
sodium channel blockers at therapeutic doses, or due to a history of hypersensitivity, or due to a history of drug or other allergy that contraindicates
their participation
Zakrzewska et al. Trials          (2018) 19:704 Page 4 of 10
sites, although the main issues experienced were similar
to those in London and Rome.
Among those who were screened, reasons for failure
also varied by site (Fig. 3).
Analysis of open-label withdrawals
Across all 25 recruiting sites, 125 patients were screened,
of whom 46.4% (58/125) did not meet study criteria for
the open-label phase. A total of 67 patients were en-
rolled, of whom 44 completed the open-label phase and
29 entered the double-blind phase [16]. In order to fur-
ther explore difficulties in retention even among individ-
uals entering the trial, we reviewed the characteristics of
individuals in the open-label population versus those
completing the open-label phase and entering the double-
blind phase (Table 2). Mean and median age were slightly
Fig. 2 Detailed breakdown of prescreening and screening results from the London cohort. No pain = TN diagnosis but no current pain (on or off
treatment); mild pain = score of 1–3; moderate pain = score of 4–7; severe pain = score of 7–10 [21]. aIncludes Fridericia’s formula requirements
(< 450 ms in two of three electrocardiograms done at screening). Abbreviations: CBZ carbamazepine, F female, GABA gabapentin, LAM
lamotrigine, M male, MS multiple sclerosis, OXC oxcarbazepine, PG pregabalin, TN trigeminal neuralgia
Fig. 3 Reasons for failure among those screened at the five core sites. ECG electrocardiogram
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higher for the open-label population than for patients en-
tering the double-blind phase (mean 58.7 vs 55.3 years
and median 60 vs 56 years, respectively). The proportion
of females was similar between the open-label and
double-blind populations (65.7 vs 65.5%, respectively).
Height, weight, and body mass index were similar across
groups.
We further assessed the timing and reasons for with-
drawals during the open-label phase. A total of 23 pa-
tients withdrew before completing the open-label phase
(day 21; Fig. 4), and approximately two-thirds of these
(15/23; 65.2%) withdrew within the first 7 days. Among
these patients, the documented reason for withdrawal
was lack of efficacy for 18 (78.3%), withdrawal of consent
for 2 (8.7%), and adverse events for 3 (13.0%). Of the
three adverse events leading to withdrawal, two were
considered probably related to the study drug (hyperten-
sion, decreased skin turgor, and dry mouth) and one was
considered to be unrelated to the study drug (dyspnea).
Discussion
Our analysis reinforces the challenges of patient recruit-
ment in a rare disease clinical trial. Recruiting data from
five countries enrolling patients for a phase IIa study
showed that a high number of patients were noneligible
at prescreening. The predominant reasons for ineligibil-
ity were diagnosis change, age > 80 years, and issues with
language, distance, and mobility. Further barriers at
screening included not meeting requirements for pain
severity, reluctance to change medication, and failure on
cardiac screening criteria. In addition, there were a high
number of dropouts early in the open-label phase (Fig. 4),
Table 2 Demographic and clinical characteristics for patients entering the open-label versus double-blind phasea
Characteristic Open-label phase
(n = 67)
Double-blind phase
(n = 29)
Age (years)
Mean (SD) 58.7 (12.4) 55.3 (14.0)
Median (range) 60 (21–79) 56 (21–74)
Sex, n (%)
Male 23 (34.3) 10 (34.5)
Female 44 (65.7) 19 (65.5)
Height (cm)
Mean (SD) 167.3 (9.4) 167.3 (9.0)
Median (range) 165.0 (144–193) 165.0 (144–186)
Weight (kg)
Mean (SD) 74.8 (14.3) 76.1 (13.4)
Median (range) 73.0 (47–107) 74.0 (55–107)
BMI (kg/m2)
Mean (SD) 26.6 (3.9) 27.1 (3.8)
Median (range) 25.9 (19–35) 27.2 (22–33)
Race, n (%)
White 64 (95.5) 28 (96.6)
African American/African heritage 1 (1.5) 1 (3.4)
Mixed race 2 (3.0) 0
TN duration (years), median (range) 6 (0–35) 6 (1–17)
Number of previous therapies for TN, median (range) 2 (1–25) 1 (1–6)
Anatomical site of TN pain, n (%)
First branch 1 (2) 1 (3)
Second branch 17 (25) 9 (31)
Third branch 17 (25) 7 (24)
First and second branches 5 (8) 3 (10)
First, second, and third branches 7 (10) 2 (7)
Second and third branches 20 (30) 7 (24)
BMI body mass index, SD standard deviation, TN trigeminal neuralgia
aFull study population published in [16]
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suggestive of potential anxiety after discontinuation of
previous medications. It is clear from this analysis that a
large number of patients must be reviewed in order to
identify eligible patients in this population and provide a
sufficient population to enroll a study population with
enough power to inform scientific decision-making.
Diagnosis change was the most common reason for pre-
screening noneligibility. These patients had an initial diag-
nosis of classical TN, but on more careful phenotyping
were found to have other types of facial pain (e.g., TN with
concomitant pain, trigeminal autonomic cephalalgias, and
multiple sclerosis). Older age was the second most fre-
quent reason for noneligibility, despite the increase in the
upper age limit to 80 years, indicative of the older demo-
graphic of the TN population. Many older patients had
other complex medical problems that affected eligibility.
Eligible patients were slightly younger than the noneligible
group, which may be related to a greater probability of
meeting exclusion criteria among older individuals. A
number of patients were prescreening failures due to dis-
tance and mobility issues, including one-fifth of patients
at the Glostrup site. The Glostrup site receives patients
with TN from all over Denmark; hence, travel time could
be up to 6 h. Some patients were also excluded because of
language issues (e.g., migrants and patients from ethnic
minority backgrounds).
Variations in screening and prescreening have several
possible explanations. Each of the five countries that
provided data for this analysis has a unique catchment
and referral system that contributes to recruitment chal-
lenges. Centralized treatment accepts patients from a
wide geographic region, thus patients who may need to
travel large distances to get to the center and who may
have issues with poor mobility may not be able to par-
ticipate in a clinical trial. Conversely, centralized treat-
ment may be of benefit in identifying patients eligible
for a trial, especially in rare diseases. In addition, some
centers chose not to perform the initial screening on pa-
tients known to have potential cardiac issues who re-
quired a substantial number of medications, accounting
for the reasonably low number of noneligible patients at
prescreening due to cardiac issues. Even so, at screening,
a number of patients were excluded because of the regu-
latory requirements for ECG parameters (particularly at
the Rome site), which may have led to more exclusions
than expected due to the older age of the population.
Among the prescreened, eligible patients in London, a
reasonable proportion did not meet requirements for
pain severity; this may be because of changes in the pain
phenotype over time since the initial diagnosis, the po-
tential for remission [19], or good control on current
therapies. Some patients with more severe pain opted to
receive surgery instead of participating in the trial. A
number of patients were also reluctant to stop their
current anticonvulsants for fear of pain increase and/or
the knowledge that they would need to return to their
old medications after completion of the trial; this was a
significant contributor to recruitment problems at the
London site. These patients had also had poor experi-
ences with gabapentin and pregabalin, which were the
only drugs that were allowed. TN pain is unique com-
pared with other chronic pain in terms of the intensity
and unpredictability of attacks, which could increase
such anxieties. In some cases, patients were unwilling to
sacrifice their time/loss of income (e.g., for those who
were self-employed) in order to attend multiple study
visits. Nationally and internationally agreed criteria for
diagnosis using published classifications could improve
the initial phenotyping of patients.
The high number of withdrawals during the open-label
phase of the trial, and particularly during the first few
days, is suggestive of further barriers to trial retention.
Fig. 4 Withdrawals over time among patients recruited into the open-label phase (full study population)
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The documented reason for withdrawal for a majority of
these patients was “lack of efficacy,” but precise reasons
were not captured. It is possible that patients’ reluctance
to proceed was related to anxiety after discontinuation
of previous medications. Concomitant use of carbamaze-
pine can decrease vixotrigine exposure, with effects
shown to persist 7 days after discontinuation of carba-
mazepine [20], which may have contributed to perceived
lack of efficacy early in the open-label phase (Fig. 4).
Analysis of demographics among the open-label popula-
tion and those entering the double-blind phase sug-
gested that younger patients may have been slightly
more likely to persist with the trial than older patients.
Additionally, the use of a fixed dose with no potential
for increase may have contributed to a lack of response.
The ability to offer a long-term extension so responders
could continue beyond the randomized controlled trial
may have made a difference, as patients would not have
had to go back on their old medication.
Recommendations for improving recruitment in future
trials are summarized in Table 3. The vixotrigine phase
III clinical trial is being designed with these recommen-
dations in mind. The knowledge that the phase IIa study
was successful and patient satisfaction was high will be
helpful.
To improve recruitment, this study employed a ran-
domized withdrawal design in order to minimize time
on placebo, of particular importance in the TN popula-
tion due to the severity of pain. However, many patients
remained reluctant to come off their current therapy in
order to participate. This was especially true for those
individuals receiving > 1000 mg of carbamazepine or
oxcarbazepine, because it is recommended that reduc-
tions are done slowly, and thus patients were fearful of
pain worsening before the start of the trial. Further ex-
ploration of innovative designs that minimize the re-
quired sample size and/or maximize the number of
patients receiving intervention could aid recruitment for
future trials in TN and other rare diseases [5, 9, 17].
Open designs whereby patients know which treatment
they are receiving have also been shown to improve re-
cruitment, but they are subject to inherent bias [2].
Other factors identified in the broader literature with
the potential to improve patients’ willingness to partici-
pate in clinical trials include good communication with
patients [6, 7], commitment to share/make public trial
results [7], dedicated research staff to support clinical
staff and patients [8], ease of involvement (e.g., weekly
vs daily diary, minimizing study visits) [6–8], the notion
of contributing to medical knowledge and helping others
[6, 8], higher satisfaction with care and physicians [7, 8],
and limited anticipated side effects of a new drug [7].
Other strategies have also shown some success in im-
proving recruitment, including telephone reminders to
nonrespondents, and opt-out, rather than opt-in, proce-
dures for contacting potential trial participants (although
opt-out procedures are controversial as they may be per-
ceived as not being truly voluntary) [2]. Direct-to-patient
Table 3 Key recommendations for improving recruitment in trigeminal neuralgia (TN) clinical trials
Barrier (real or perceived) Strategy
Patients with the opportunity to try study drug have to return to prior
treatment at study completion
• Only true for phase II and earlier studies
• Phase III studies should be designed with the option of a long-term
extension
Required discontinuation of current therapy during the trial run-in phase • Consider permitting use of and incorporating a higher/loading dose
of the study drug to offset potential reduction in exposure owing to
prior/concomitant medications
• Implementation of a downtitration and uptitration algorithm of
concomitant medications and study drug, respectively
Change in diagnosis from TN to other types of TN
• The TN phenotype is also known to change over time, with potential for
remission [22], which could alter whether patients meet pain requirements
• Recruitment of patients with recent visits to the clinic versus database
records
Only specialists are recruiting patients attending specialist clinics • Local primary care practices could be encouraged to telephone
potential patients
○ A nurse could administer a semistructured questionnaire to identify
potential cases for referral to the specialist center
Prescreening eligibility and screening failures inconsistently captured • Implementation of a central project management and coordination
system with prescreening and screening data locks that are promptly
reviewed
Patient diary too large a burden • Patient diaries less onerous (e.g., by not requiring documentation of
all individual attacks, but rather average daily pain, or not requiring
documentation of each attack after a certain threshold
(e.g., > 20 attacks))
Lack of time or inability to attend study visits owing to distance/mobility • Replace some onsite visits with telephone visits
• Consider patient compensation for time loss and/or travel/dietary
expenses
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recruitment has been tried, utilizing a web-based ap-
proach to patient recruitment in which social media and
foundation sites were used to reach out to patients dir-
ectly, rather than through treatment centers [19]. Unfor-
tunately, in this study, direct-to-patient recruitment was
not as successful as recruitment through treatment cen-
ters and the authors suggest that further research using
this method of recruitment is needed.
It is critical that investigators and authors evaluate and
publicly share their recruiting strategies and difficulties
when reporting clinical trials in order to inform other
studies and support contextualization of data [4, 18].
These data must be interpreted with reasoned caution.
This analysis of prescreening eligibility and screening
failure was reliant on site logs; data were not formally
databased for this study and complete records were not
available for all recruiting sites. In addition, the reasons
for noneligibility and screening failures may not have
been captured consistently across sites.
Conclusions
Recruitment challenges encompass not only motivating
patients in participation and passing screening require-
ments, but also retaining them in the study once enrolled.
A number of factors contributed to difficulties in recruit-
ment in this phase IIa study in patients with TN, including
diagnosis changes; issues relating to distance, language,
and mobility; and anxieties over changing therapeutic
regimen. Efforts should be made in future trials to over-
come these barriers where possible. Centers with large
numbers of patients are needed.
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